Cancer In Vitro Diagnostics (IVD) Market Research Reveals Path To $19.85 Billion By 2030

The cancer in vitro diagnostics (IVD) market is on track for significant expansion over the coming years. Advancements in technology and a growing focus on personalized medicine are driving this sector toward substantial growth, with promising innovations enhancing cancer detection and treatment.

Projected Market Size and Growth of the Cancer In Vitro Diagnostics IVD Market
The cancer in vitro diagnostics (IVD) market is expected to reach $19.85 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.7%. This upward trajectory is fueled by rising demand for personalized oncology diagnostics, increased investments in genomic sequencing technologies, and the broadening availability of point-of-care cancer testing. Additionally, the integration of cloud-based diagnostic platforms and a stronger emphasis on precision medicine contribute to this growth. Emerging patterns in the market include widespread adoption of molecular and genomic cancer tests, a surge in companion diagnostics, growing use of AI-driven data analytics, expanded applications of liquid biopsies, and intensified efforts toward early cancer detection.

The cancer in vitro diagnostics (ivd) market size has grown strongly in recent years. It will grow from $14.32 billion in 2025 to $15.32 billion in 2026 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to expansion of hospital diagnostic infrastructure, growth in biomarker-based testing, adoption of PCR and immunoassay technologies, rising cancer screening programs, improved laboratory automation.

Download a free sample of the cancer in vitro diagnostics (ivd) market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27234&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Factors Stimulating Growth in the Cancer In Vitro Diagnostics Market
One major factor driving market development is the rising need for personalized diagnostics in oncology, which enables tailored treatment plans for cancer patients. This personalized approach has led to increased investments in genomic sequencing and precision testing technologies.
Furthermore, the expansion of point-of-care testing platforms and cloud-based diagnostic solutions is simplifying access to timely results and improving overall diagnostic efficiency. These advancements support a shift toward more patient-centric cancer care and accelerate the adoption of innovative diagnostic tools.

Prominent Players in the Cancer In Vitro Diagnostics IVD Market
Several leading companies are shaping the landscape of cancer in vitro diagnostics, including F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., Illumina Inc., Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., Tulip Diagnostics Pvt Ltd., Guardant Health Inc., Agilent Technologies Inc., and BGI Genomics.
A notable partnership occurred in June 2025 when QIAGEN N.V., a Netherlands-based molecular diagnostics and life sciences company, joined forces with South Korea's Gencurix Co., Ltd. Together, they are working to develop QIAcuity Digital PCR IVD assays. This collaboration combines QIAGEN's digital PCR technology with Gencurix's expertise in biomarker discovery and assay development, aiming to accelerate innovation in molecular testing and precision clinical applications.

View the full cancer in vitro diagnostics (ivd) market report:
https://www.thebusinessresearchcompany.com/report/cancer-in-vitro-diagnostics-ivd-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Current Trends Driving Innovation in the Cancer In Vitro Diagnostics Industry
Major players in this market are emphasizing advancements in cancer screening technologies, especially focusing on blood-based colorectal cancer (CRC) tests that offer non-invasive, accurate early detection options. These tests identify cancer-related molecular markers such as circulating tumor DNA (ctDNA) in blood samples to detect colorectal cancer effectively in individuals with average risk.
For example, in July 2024, Guardant Health, Inc., a precision oncology company based in the United States, received FDA approval for its Guardant Shield blood test, designed for primary colorectal cancer screening. This test analyzes ctDNA methylation patterns and other tumor-derived markers with features like noninvasive sample collection, high analytical precision, and integration with clinical workflows. It aims to improve patient compliance, enable earlier cancer detection, reduce late-stage diagnoses, and qualifies for Medicare reimbursement, thereby expanding access to screening among the general population.

Overview of Segments in the Cancer In Vitro Diagnostics IVD Market Report
The report segments the cancer in vitro diagnostics market into the following categories:
1) Product Type: Reagents and Kits, Instruments, Software and Services
2) Technology: Clinical Chemistry, Immunochemistry/Immunoassays, Hematology, Coagulation and Hemostasis, Cytogenetics/Liquid Biopsy Technologies, Molecular Diagnostics, and Other Technologies
3) Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer
4) End-Users: Hospitals, Laboratories, Academic Institutions, Point-of-Care Testing Facilities, Specialty Oncology Diagnostic Centers, and Others

Further detailing includes:
- Reagents and Kits subcategories such as PCR, NGS, Immunoassay, In Situ Hybridization (ISH), and others
- Instruments like PCR instruments, NGS instruments, Immunoassay Analyzers, ISH instruments, and more
- Software and Services covering Data Analysis Software, Laboratory Information Management Systems, Cloud-Based Data Management, Instrument Integration Software, and Support and Maintenance Services

This detailed segmentation offers a comprehensive view of the market's structure, catering to the diverse needs of cancer diagnostics worldwide.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.